

Dear Sir/Madam

Our position regarding the rescheduling of CBD products is that if the product becomes an over the counter product, the research will greatly diminish. If it remains in the hands of medical practitioners then scientific research can effectively continue.

We are still learning of the many health benefits of the cannabis plant and CBD and this will continue if guided and controlled by the research and medical industry.

Best Regards

Alessandro Sorbello

Managing Director